Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Reexamination Certificate
2006-04-11
2006-04-11
Saeed, Kamal A. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
C558S303000, C544S106000
Reexamination Certificate
active
07026516
ABSTRACT:
Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight reduction, obsessive-compulsive disorder, various forms of depression, traumatic brain injury, stroke, and narcolepsy.
REFERENCES:
patent: WO 98/06689 (1998-02-01), None
Acton, et al., “Single-Photon Emission Tomography Imaging of Serotonin Transporters in the Nonhuman Primate Brain With [123l]ODAM,” European Journal of Nuclear Medicine, 26:1359-1362 (1999).
Basaif, et al., International Journal of Chemistry, 6:55-65 (1995) (XP002209431)—Abstract.
Biederman, M.D., “Attention-Deficit/Hyperactivity Disorder: A Life Span Perspective,” J. Clin. Psychiatry, 59:4-16 (1998).
Bogeso, et al., “3-Phenyl-1-Indanamines. Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake,” J. Med. Chem., 28:1817-1828 (1985).
Breslow, et al. Journal of Organic Chemistry, (XP002209567), 26:679-681 (1961).
Canfield, et al. “Autoradiographic Localization of Cocaine Binding Sites by [3H]CFT ([3H]WIN 35,428) in the Monkey Brain,” Synapse, 6:189-195 (1990).
Corson, et al., Journal of Organic Chemistry (XP002209566), 27:1636-1640 (1962).
Coyle, et al., “Catecholamine Uptake by Synaptosomes in Homogenates of Rate Brain: Stereospecificity in Different Ares,” The Journal of Pharmacology and Experimental Therapeutics, vol. 170 (1969).
Cyr, et al., “Current Drig Therapy Recommendations for the Treatment of Attention Deficit Hyperactivity Disorder,” Drugs, 56:215-223 (1998).
Ficini, “Laborratoire de Chimie Structurale, Faculte des Sciences; Paris,” 5e, pp. 119-124 (1956).
Fischman, et al., “Rapid Detection of Parkinson's Disease by SPECT With Altropane: A Selective Ligand for Dopamine Transporters,” 29:128-141 (1998).
Gehlert, et al., “The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding,” The Journal of Pharmacology and Experimental Therapeutics, 287:127 (1998).
Ghosh, et al., Tetrahedron Letters, 41:8425-8429 (2000).
Giros, et al., “Hyperlocomotion and Indifference to Cocaine and Amphetamine in Mice Lacking the Dopamine Transporter,” Nature, 379:606-612 (1996).
Hadrich, et al., “Synthesis and Characterization of Fluorescent Ligands for the Norepinephrine Transporter: Potential Neuroblastoma Imaging Agents,” J. Med. Chem., 42:3101-3108 (1999).
Heinz, et al., “Reduced Central Serotonin Transporters in Alcoholism,” American Journal of Psychiatry, 155:1544-1549 (1998).
Hirschfeld, M.D., “Care of the Sexually Active Depressed Patient,” J. Clin. Psychiatry, 60:32-35 (1999).
Jorenby, et al., “A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation,” The New England Jounal of Medicine, 340:685-691 (1999).
Kaufman, et al., “Severe Depletion of Cocaine Recognition Sites Associated with the Dopamine Transporter 1 Parkinson's Diseased Striatum,” Synapse, 9:43-49 (1991).
Kung, H.F., “Synthesis of New Bis(aminoethanethiol) (BAT) Derivatives: Possible Ligands for99mTc Brain Imaging Agents,” J. Med. Chem. 28:1280-1284 (1985).
Madras, et al., “Cocaine Receptors Labeled by [3H]2β-Carbomethoxy-3β-(4-fluorophenyl)tropane,” Molecular Pharmacology, 36:518-524 (1989).
Madras, et al., “Technepine: A High-Affinity99mTechnetium Probe to Label the Dopamine Transporter in Brain by SPECT Imagine,” Synapse, 22:239-245 (1996).
Madras, et al., “Nitrogen-Based Drugs Are Not Essential for Blockade of Monoamine Transporters,” Synapse, 24:240-248 (1996).
Malison, et al., “Reduced Brain Serotonin Transporter Availability in Major Depression as Measured by [123I ]- 2β-Carbomethoxy-3β-(4-Iodophenyl)tropane and Single Photon Emission Computed Tomography,” Biological Psychiatry, 44:1090-1098 (1998).
McAfee, et al., “Sustained Release Bupropion for Smoking Cessation,” New England Journal of Medicine, 338:619 (1998).
McCann, U.D., “Positron Emission Tomographic Evidence of Toxic Effect of MDMA (“Ectstasy”) on Brain Serotonin Neurons in Human Beings,” The Lancet, 352:1433-1437 (1998).
McOmie, et al., Tetrahedron, (XP000567035) 24:2289-2292 (1968).
Muller, et al., Journal of Organic Chemistry, 16:1003-1024 (1950).
O'Neil, et al., “Preparation and Structural Characterization of Monoamine-Monoamide Bis(thiol) Oxo Complexes of Technetium (V) and Rhenium(V),” Inorganic Chemistry, 33:319-323 (1994).
O'Neil, et al., “Progestin Radiopharmaceuticals Labeled with Technetium and Rhenium: Synthesis, Binding Affinity, and in Vivo Distribution of a New Progestin N2S2-Metal Conjugate,” Bioconjugate, 5:189-193 (1994).
Oya, et al., “A New Single-Photon Emission Computed Tomography Imaging Agent for Serotonin Transporters: [123I]IDAM, 5-Iodo-2-((2-((dimethylamino)methyl)-phenyl)thio)benzyl Alcohol,” Journal of Medicinal Chemistry, 42:333-335 (1999).
Raffel, et al., “Influence of Vesicular Storage and Monoamine Oxidase Activity on [11C]Phenylephrine KInetics: Studies in Isolated Rat Heart,” The Journal of Nuclear Medicine, 40:323-330 (1999).
Riggs, et al., “An Open Trial of Bupropion for ADHD in Adolescents with Substance Use Disorders and Conduct Disorder,” Journal of the American Academy of Child and Adolescent Psychiatry, 37:1271-1278 (1999).
Seeman, et al., “Anti-Hyperactivity Medication: methylphenidate and Amphetamine,” Molecular Psychiatry, 3:386-396 (1998).
Seibyl, et al. “Decreased Single-Photon Emission Computed Tomographic [123l ]β-CIT Striatal Uptake Correlates with Symptom Severity in Parkinson's Disease,” Annals of Neurology, 38:589-598 (1995).
Semple, et al., “Reduced In Vivo Binding to the Serotonin Transporter in the Cerebral Cortex of MDMA (‘ecstacy’) Users,” The British Journal of Psychiatry, 175:63-69 (1999).
Szabo, et al., “Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand,” Journal of Cerebral Blood Flow and Metabolism, 19:967-981 (1999).
Walter, et al., Journal of Medicinal Chemistry, (XP002209564) 17:459-463 (1974).
Zwiebrak, et al., Journal of Organic Chemistry, (XP002209563) 28:3392-3399 (1963).
Blundell Paul
Madras Bertha K.
Meltzer Peter C.
Wang Pinglang
Edwards Angell Palmer & & Dodge LLP
Neuner, Esq. George W.
Organix Inc.
President and Fellows of Harvard College
Saeed Kamal A.
LandOfFree
Compounds with high monoamine transporter affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds with high monoamine transporter affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds with high monoamine transporter affinity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598151